Stock Markets February 24, 2026

Premarket: Home Depot, Keurig Dr Pepper and AMD Lead Gains as Markets Rebound; Novo Nordisk Slides

U.S. futures tick up after a selloff as investors weigh trade uncertainty and AI disruption risks; several corporate results and outlooks move individual stocks

By Caleb Monroe HD KDP DOCN AMD
Premarket: Home Depot, Keurig Dr Pepper and AMD Lead Gains as Markets Rebound; Novo Nordisk Slides
HD KDP DOCN AMD

U.S. stock futures inched higher Tuesday following a prior session selloff, with investors parsing uncertainty around global trade and concerns about AI-driven disruption. Corporate reports and company-specific developments pushed a number of names in premarket trading: Home Depot, Keurig Dr Pepper and AMD posted notable gains, while Novo Nordisk, Planet Fitness and other issuers fell on downgrades or softer outlooks.

Key Points

  • U.S. futures rose modestly after a prior selloff amid concerns over global trade and AI-related disruption.
  • Several corporate reports and company developments drove premarket movers: Home Depot, Keurig Dr Pepper and AMD gained, while Novo Nordisk, Planet Fitness and others declined.
  • Sectors most affected include consumer retail/home improvement, beverages/consumer packaged goods, semiconductors, cloud infrastructure, healthcare/pharmaceuticals, fitness services and electronic test equipment.

U.S. stock futures were modestly higher Tuesday, recovering from the prior session's declines as market participants processed heightened uncertainty over global trade and lingering concerns about disruptions from artificial intelligence.


Market movers in premarket trading

  • Home Depot (NYSE:HD) - The home-improvement retailer's shares rose 2.1% after it reported fourth-quarter results that beat expectations and reiterated its full-year guidance. The company cited steady demand from consumers facing tighter budgets as a supporting factor.
  • Novo Nordisk (CSE:NOVOb) - Shares fell 2.9% after JPMorgan lowered its rating to 'neutral' from 'overweight.' The downgrade followed late-stage data for the obesity drug CagriSema that were described as disappointing and showed the treatment to be less competitive than Eli Lilly's Zepbound.
  • Keurig Dr Pepper (NASDAQ:KDP) - The soft-drinks firm climbed 2.1% after posting fourth-quarter results above expectations and providing revenue guidance for fiscal 2026 that investors found encouraging, in part based on the expected acquisition of JDE Peet's.
  • DigitalOcean (NYSE:DOCN) - The cloud infrastructure provider's shares slipped 1.4% despite reporting Q4 results that exceeded forecasts and raising its revenue outlook for both 2026 and 2027. The stock has gained more than 23% year to date.
  • Advanced Micro Devices (NASDAQ:AMD) - AMD jumped 10% after reaching an agreement to sell up to $60 billion worth of artificial-intelligence chips to Meta Platforms over a five-year period under terms that also permit Meta to buy as much as 10% of the chip company.
  • Planet Fitness (NYSE:PLNT) - The fitness-center operator's stock dropped 4.9% after issuing a 2026 outlook that investors judged disappointing, even though fourth-quarter results beat expectations.
  • Keysight Technologies (NYSE:KEYS) - Shares surged 13% after the electronic-equipment maker projected second-quarter profit ahead of Wall Street estimates.
  • Hims Hers Health (NYSE:HIMS) - The telehealth company's shares fell 4.3% after it forecast first-quarter revenue that was below analyst estimates.

The premarket action underscored how company-level news - earnings beats, forward guidance and large commercial agreements - can drive outsized moves for individual stocks even as broader macro uncertainties, including trade tensions and AI-related disruption fears, weigh on overall market sentiment.

Investors continue to react to both fundamental operating signals and analysts' reassessments of competitive dynamics, as seen in the downgrade of Novo Nordisk following trial results that altered expectations for its obesity treatment relative to a key competitor.

Risks

  • Ongoing uncertainty around global trade and AI-driven disruption could continue to pressure broader market sentiment - this affects multiple sectors including technology and consumer cyclical industries.
  • Company-specific clinical trial results and analyst ratings revisions can materially alter investor expectations for healthcare and biotechnology stocks, as illustrated by Novo Nordisk's downgrade after late-stage obesity drug data.
  • Disappointing forward guidance from operators in consumer services or telehealth can lead to sharp premarket declines, shown by Planet Fitness' and Hims Hers Health's reactions to their respective outlooks.

More from Stock Markets

Morgan Stanley Shifts to Cautious on Global Gas; Flags Excelerate Energy as Relative Winner Feb 24, 2026 Anthropic Rolls Out 10 Enterprise Plug-ins as It Pushes Into Autonomous AI for Businesses Feb 24, 2026 Ideal Power Shares Drop After Company Prices $14 Million Equity Package Feb 24, 2026 Meta Commits Up to $60 Billion in AI Chips to AMD, Including Option for Equity Stake Feb 24, 2026 MacroGenics Shares Drop After FDA Imposes Partial Clinical Hold on LINNET Trial Feb 24, 2026